Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma

OBJECTIVES: Among advanced multiple myeloma (MM) patients, B-cell maturation antigen (BCMA) specific targets like Belantamab Mafodotin (belamaf) and CAR T-cell therapies have been shown to improve clinical outcomes, but at significant costs. To compare the expected costs per quality-adjusted life ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapinos, Kandice A., Hu, Ellen, Trivedi, Jigar, Geethakumari, Praveen Ramakrishnan, Kansagra, Ankit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869188/
https://www.ncbi.nlm.nih.gov/pubmed/36651055
http://dx.doi.org/10.1177/10732748221142945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869188/
https://www.ncbi.nlm.nih.gov/pubmed/36651055
http://dx.doi.org/10.1177/10732748221142945

Ejemplares similares